Bioanalytics, Metabolomics & Pharmacokinetics (BMPK) Publications

• Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol. 2019 Feb;42(2):184-189. doi: 10.1097/COC.0000000000000492 PMCID: PMC6345595

• Cook SF, Fiandalo MV, Watt DS, Wu Y, Mohler JL, Bies RR. Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects. Prostate. 2018 Jun 25. doi: 10.1002/pros.23665. [Epub ahead of print] PMID: 29938815

• Hess TA, Drinkhouse ME, Prey JD, Miller JM, Fettig AA, Carberry CA, Brenn SH, Bailey DB. Analysis of platinum content in biodegradable carboplatin-impregnated beads and retrospective assessment of tolerability for intralesional use of the beads in dogs following excision of subcutaneous sarcomas: 29 cases (2011-2014). J Am Vet Med Assoc. 2018 Feb 15;252(4):448-456. doi: 10.2460/javma.252.4.448 PMID: 29393745

• Fiandalo MV, Wilton JH, Mantione KM, Wrzosek C, Attwood KM, Wu Y, Mohler JL. Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models. Prostate. 2018 Feb;78(3):213-221. doi: 10.1002/pros.23459. Epub 2017 Dec 1 PMCID: PMC5768451

• Fiandalo MV, Stocking JJ, Pop EA, Wilton JH, Mantione KM, Li Y, Attwood KM, Azabdaftari G, Wu Y, Watt DS, Wilson EM, Mohler JL. Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade. Oncotarget. 2018 Jan 10;9(13):11227-11242. doi: 10.18632/oncotarget.24107. eCollection 2018 Feb 16 PMCID: PMC5834294

• Vicky C. Chang, Michelle Cotterchio, Beatrice A. Boucher, David J. A. Jenkins, Lucia Mirea, Susan E. McCann & Lilian U. Thompson (2018) Effect of Dietary Flaxseed Intake on Circulating Sex Hormone Levels among Postmenopausal Women: A Randomized Controlled Intervention Trial, Nutrition and Cancer, DOI: 10.1080/01635581.2018.1516789

• Kim W, Zhang L, Wilton JH, Fetterly G, Mohler J, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark A, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014;20:24 6269-6276.  PMID: 25336698

• Fiandalo MV, Wilton J, Mohler JL. Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment.  Int J Biol Sci. 2014;10(6):596-601. doi:10.7150/ijbs.8780 PMID: 24948872

•McCann SE, Edge SB, Hicks DG, Thompson LU, Morrison CD, Fetterly G, Andrews C, Clark K, Wilton J, Kulkarni S. A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers. Nutr Cancer; 2014;66(4):566-75. doi: 10.1080/01635581.2014.894097. Epub 2014 Mar 26. PMID: 24669750

•Wilton J, Kurenova E, Pitzonka L, Gaudy A, Curtin L, Sexton S, Cance W, Fetterly G. Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. European J Drug Metab Pharmacokinet. 2014 Nov 7. [Epub ahead of print] PMID: 25377246

•Wilton JH, Titus MA, Efstathiou E, Fetterly GJ, Mohler JL.  Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. Prostate. 2014 May;74(7):722-31. PMID:24847527

•Wu Y, Godoy A, Azzouni F, Wilton JH, Ip C, Mohler JL. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Prostate. 2013 Sep;73(13):1470-82. doi: 10.1002/pros.22694. Epub 2013 Jun 27. PMID: 23813697

•Patrzyc HB1, Dawidzik JB, Budzinski EE, Freund HG, Wilton JH, Box HC. Covalently linked tandem lesions in DNA. Radiat Res. 2012 Dec;178(6):538-42. doi: 10.1667/RR2915.1. Epub 2012 Oct 29. PMID: 23106212

•Antonarakis ES, Heath EI, Posadas EM…Yu EY, Wilding GE, Fetterly GJ, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 2013; 71(4):883-92. PMCID: PMC3609871

•Bistulfi G, Diegelman P, Foster BA, Kramer DL, Porter CW, Smiraglia DJ. Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools. FASEB J. 2009 Sep; 23(9):2888-97. PMCID: PMC2735368

•Brem EA, Thudium K, Khubchandani S… Fetterly G, Czuczman MS, Hernandez-Illizaliturri, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and –resistant lymphomas. British J of Haematology. 2011; 153 (5): 599-611. PMCID: PMC3092002

•Chadha MK, Fakih M, Muindi J, Tian L, Mashtare T, Johnson CS, Trump D. Effect of 25-hydroxyvitamin D status on serological response to influenza vaccine in prostate cancer patients. Prostate 2011; 71(4): 368-72. PMID: 20812224

•Fakih MG, Andrews C, McMahon J, Muindi JR. A prospective clinical trial of cholecalciferol 2000 IU/day in colorectal cancer patients: evidence of a chemotherapy-response interaction. Anticancer Res 2012; 32(4): 1333-8. PMID: 22493367

•Fakih MG, Fetterly G, Egorin MJ, Muindi J, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res 2010; 16(14): 3786-94. PMCID: PMC2931804

•Fakih MG, Groman A, McMahon J, Wilding G, Muindi JR. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemother Pharmacol 2012; 69(3):743-51. PMID: 22020318

•Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int J Colorectal Dis 2009; 24(2):219-24. PMCID: PMC2715947

•Fetterly GJ, Aras U, Lal D, Murphy M, Meholick PD, Wang ES. Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia. AAPS J 2013. PMID: 23550025

•Lal D, Park JA, Demock K, Marianaro J, Perez AM, Lin M, Tian L, Mashtare TJ, Murphy M, Prey J, Wetzler M, Fetterly GJ, Wang ES. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Mol Cancer Ther 2010; 9(10): 2737-51. PMID: 20924124

•Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res 2010; 70(14):5953-62. PMCID: PMC2928678

•Marshall JR, Ip C, Romano K…Fetterly G, et al. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prev Res (Phila) 2011; 4(11): 1938-44. PMCID: PMC3208773

•Mhawech-Fauceglia P, Wang D, Kesterson J, Clark K, Monhollen L, Odunsi K, Lele S, Liu S. Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PLoS One. 2010 Nov 8; 5(11):e15415. PMCID: PMC2975707

•Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 2009; 65(1): 33-40. PMCID: PMC2746253

•Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL, Johnson CS. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 2010; 151(9): 4301-12. PMCID: PMC2940491

•Naing A, Cohen R, Dy GK, et al. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs 2013. PMID: 23361621

•Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander B, Repasky E, Ma WW, Jusko WJ. Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol 2013. PMID: 23455452

•Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander B, Repasky E, Ma WW, Jusko WJ. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemother Pharmacol 2013. PMID: 23455451

•Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells. AAPS J 2013; 15(1):78-84. PMCID: PMC3535103

•Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ. Interactions of Everolimus and Sorafenib in Whole Blood Lymphocyte Proliferation. Pharm Res 2013 30(3): 707-13. PMID: 23151723

•Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M. Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling. Leuk Res 2012; 36(11): 1410-6. PMCID: PMC3457067

•Tummala R, Diegelman P, Hector S, Kramer D, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L. Combination effects of platinum drugs and N (1), N (11) diethylnorspermine on spermidine/spermine N (1)-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. Cancer Chemother Pharmacol 2011; 67(2): 401-414. PMCID: PMC3028085

•Weickhardt A, Doebele R, Oton A…Dy G, Adjei A, Fetterly G, et al. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2012; 7(2): 419-26. PMCID: PMC3358820

•Yu WD, Ma Y, Flynn G, Muindi JR, Kong RX, Trump DL, Johnson CS. Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system. Cell Cycle 2010; 9(15):3022-9. PMCID: PMC3040927